Treatment of genotype 1 hepatitis C virus (HCV) infection with combination direct acting anti-virals is associated with very high rates of sustained virological response.
Daily combination of ledipasvir and sofosbuvir for 12 weeks is approved for the treatment of genotype 1 HCV patients, though noncirrhotic patients who are naļve to treatment with a baseline HCV RNA <6 million IU/mL can be treated for 8 weeks.
Dr Curry and colleagues from Massachussetts, USA provided guidance stemmed from a post hoc analysis of the ION 3 clinical trial, which demonstrated similar sustained virological response for patients treated with ledipasvir and sofosbuvir with or without ribavirin for 8 or 12 weeks.
|Sofosbuvir and achieved sustained virological response rate of 95%|
|Alimentary Pharmacology & Therapeutics|
The researchers compared the sustained virological response for 8 weeks vs 12 weeks of ledipasvir and sofosbuvir in HCV infected patients in a real-world setting.
The research team performed an observational real-world cohort study of treatment success following 8 or 12 weeks of ledipasvir and sofosbuvir for treatment-naļve genotype 1 HCV patients.
A total of 826 patients were treated for either 8 or 12 weeks with ledipasvir, and sofosbuvir and achieved sustained virological response rate of 95%, and there was no statistical difference in sustained virological response rates in the 2 groups irrespective of any clinical or virological variables.
Dr Curry's team concludes, "In treatment-naļve HCV genotype 1 patients, sustained virological response was 95% in those treated for either 8 weeks or 12 weeks with ledipasvir and sofosbuvir."
"We found that 8 week ledipasvir and sofosbuvir can reduce costs without compromizing outcomes for those patients who qualify for such regimen."